Daina Graybosch, Ph.D., is a Senior Research Analyst at SVB Leerink covering Immuno-Oncology. Prior to joining the firm in 2018, Dr. Graybosch worked at McKinsey & Company as a Senior Expert and Head of Mckinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, Dr. Graybosch developed several McKinsey solutions that bring data and advanced analytics to pharmaceutical development decisions.
About 10,000 newly diagnosed gastric/GEJ cancer patients are treated each year in the U.S., with about a quarter being HER2-positive. That represents a $300 million opportunity.21 May 2021
We know the antibodies are likely less effective, but maybe the T cells can save us. It makes sense biologically. We don't have the data, but we can hope. Some coronavirus vaccine developers are already looking at ways to develop next-generation vaccines that stimulate T cells more effectively. Antibodies detect only proteins outside cells, and many coronavirus vaccines target a protein called spike that decorates the surface of the virus. But the spike protein is "quite variable", suggesting that it might be prone to mutating, says Karlsson, and raising the risk that emerging variants will be able to evade antibody detection.21 May 2021